- Home
- TCRX vs ICAD Comparison
TCRX vs ICAD Comparison
Compare TCRX & ICAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- ICAD
- Stock Information
- Founded
- TCRX 2018
- ICAD 1984
- Country
- TCRX United States
- ICAD United States
- Employees
- TCRX N/A
- ICAD N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- ICAD Medical/Dental Instruments
- Sector
- TCRX Health Care
- ICAD Health Care
- Exchange
- TCRX Nasdaq
- ICAD Nasdaq
- Market Cap
- TCRX 100.7M
- ICAD 103.3M
- IPO Year
- TCRX 2021
- ICAD 1986
- Fundamental
- Price
- TCRX $1.44
- ICAD $3.69
- Analyst Decision
- TCRX Strong Buy
- ICAD Hold
- Analyst Count
- TCRX 6
- ICAD 1
- Target Price
- TCRX $9.50
- ICAD N/A
- AVG Volume (30 Days)
- TCRX 470.2K
- ICAD 317.8K
- Earning Date
- TCRX 08-11-2025
- ICAD 08-12-2025
- Dividend Yield
- TCRX N/A
- ICAD N/A
- EPS Growth
- TCRX N/A
- ICAD N/A
- EPS
- TCRX N/A
- ICAD N/A
- Revenue
- TCRX $4,421,000.00
- ICAD $19,528,000.00
- Revenue This Year
- TCRX $159.20
- ICAD $3.60
- Revenue Next Year
- TCRX N/A
- ICAD N/A
- P/E Ratio
- TCRX N/A
- ICAD N/A
- Revenue Growth
- TCRX N/A
- ICAD 8.86
- 52 Week Low
- TCRX $1.02
- ICAD $1.18
- 52 Week High
- TCRX $7.89
- ICAD $4.02
- Technical
- Relative Strength Index (RSI)
- TCRX 44.26
- ICAD 48.84
- Support Level
- TCRX $1.44
- ICAD $3.68
- Resistance Level
- TCRX $1.61
- ICAD $3.88
- Average True Range (ATR)
- TCRX 0.16
- ICAD 0.13
- MACD
- TCRX -0.02
- ICAD -0.05
- Stochastic Oscillator
- TCRX 10.44
- ICAD 3.12
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About ICAD iCAD Inc.
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment includes image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.